$ alzcure是通過分散科學（DESCI）為阿爾茨海默氏症研究的開創性區塊驅動的資金

它建立在Solana的基礎上，可以使社區驅動的基因療法和神經元再生的支持。

The initiative, operating on a decentralized funding model, aims to ensure that researchers, biotech firms, and investors can collaborate smoothly in a Web3 ecosystem. By ensuring real-time financial support for high-impact research projects and streamlining the administrative burden, Alzheimer's Cure Charity Token is aiming to transform how medical research is funded and executed.

該計劃以分散的資金模型運行，旨在確保研究人員，生物技術公司和投資者可以在Web3生態系統中平穩地合作。通過確保對高影響力研究項目的實時財政支持並簡化行政負擔，阿爾茨海默氏症的Cure Charity Charity Token的目標是改變醫學研究的資金和執行方式。

With a focus on epignetic therapies and neuron regeneration, including the study of Yamanaka Factors for restoring lost neuronal function, the project is also funding research into gene therapy and regenerative medicine solutions for Alzheimer's disease and other neurodegenerative conditions.

該項目側重於靜脈療法和神經元再生，包括研究雅馬卡因恢復神經元功能喪失的因素的研究，該項目還為阿爾茨海默氏病和其他神經退行性疾病的基因療法和再生醫學解決方案提供資金。

This endeavor aligns with the broader goal of moving beyond symptom management and developing disease-modifying therapies that could fundamentally alter the course of neurodegenerative diseases like Alzheimer's.

這項工作與超越症狀管理和開發疾病改良療法的更廣泛的目標相吻合，這些療法可能從根本上改變了像阿爾茨海默氏症這樣的神經退行性疾病。

The process of securing traditional research funding is often deemed slow, bureaucratic, and highly competitive, rendering access to critical resources scarce. Despite billions invested in Alzheimer's research over the years, a cure remains elusive, and most treatments concentrate on managing symptoms rather than addressing the root causes of neurodegeneration.

獲得傳統研究資金的過程通常被認為是緩慢，官僚和競爭激烈的，使得獲得關鍵資源的機會很少。儘管多年來對阿爾茨海默氏症的研究進行了數十億美元的投資，但治愈仍然難以捉摸，大多數治療方法都集中於管理症狀，而不是解決神經退行性的根本原因。

In response to these challenges, Alzheimer's Cure Charity Token is introducing a decentralized, blockchain-powered funding model that ensures direct, traceable, and instant financial support for promising research initiatives. Through smart contracts, Alzheimer's Cure Charity Token facilitates seamless transactions, reducing administrative overhead and ensuring that funding reaches researchers without unnecessary delays.

為了應對這些挑戰，阿爾茨海默氏症的CURE CHARITY CHARITY TOKEN引入了一個分散的區塊鏈供電的資金模型，可確保直接，可追溯和即時的財務支持，以實現有前途的研究計劃。通過智能合約，阿爾茨海默氏症的治療慈善機構令牌有助於無縫交易，減少行政開銷，並確保資金在沒有不必要的延遲的情況下到達研究人員。

One of the key areas of focus for Alzheimer's Cure Charity Token is cellular reprogramming and neuron regeneration, particularly through the study of Yamanaka Factors, a Nobel Prize-winning discovery in epigenetics that has shown potential in restoring lost neuronal function. By funding research into gene therapy, regenerative medicine, and advanced medical solutions, Alzheimer's Cure Charity Token is aiming to move beyond symptom management and toward disease-modifying therapies.

阿爾茨海默氏症治療慈善令牌的關注點之一是細胞重編程和神經元再生，尤其是通過研究Yamanaka因素，Yamanaka因素是表觀遺傳學中諾貝爾獎獲獎的發現，其潛力在恢復了損失的Neuronal功能方面。通過資助基因療法，再生醫學和先進的醫療解決方案的研究，阿爾茨海默氏症的治療慈善機構令牌的目的是超越症狀管理和疾病改良療法。

Key Features of $ALZcure

$ alzcure的主要功能

* Blockchain-Powered Research Grants - Smart contracts facilitate direct and secure funding for high-impact projects.

*由區塊鏈驅動的研究補助金 - 智能合約有助於直接和確保高影響力項目的資金。

* Decentralized Community Governance - Token holders can participate in voting and decision-making regarding fund allocation and research priorities.

*分散的社區治理 - 代幣持有人可以參與有關基金分配和研究優先事項的投票和決策。

* Focus on Gene Therapy & Neurodegeneration - Supporting research into Alzheimer's, Parkinson's, Dementia, Stroke, ALS, Multiple Sclerosis (MS), Huntington's disease, and other neurodegenerative conditions.

*專注於基因治療和神經退行性 - 支持對阿爾茨海默氏症，帕金森氏症，癡呆症，中風，ALS，多發性硬化症（MS），亨廷頓氏病和其他神經退行性疾病的研究。

* Staking and Rewards Mechanism - Holders can stake $ALZcure tokens to earn rewards while contributing to long-term research funding.

*積分和獎勵機制 - 持有人可以將$ alzcure代幣持有獎勵，同時為長期研究資金做出貢獻。

* Transparency & Speed - Blockchain-based transactions ensure efficient, real-time financial distribution with full traceability.

*透明度和速度 - 基於區塊鏈的交易可確保具有完整可追溯性的高效實時財務分配。

The Urgent Need for Innovation in Alzheimer's Research

阿爾茨海默氏症研究的迫切需要

Alzheimer's disease currently affects over 55 million people worldwide, and this number is expected to triple by 2050. Despite substantial investments in research, progress in developing effective treatments remains slow, and most available therapies provide only temporary relief from symptoms rather than addressing the underlying causes of neurodegeneration.

阿爾茨海默氏病目前在全球範圍內影響超過5500萬人，預計到2050年，這一數字將在研究中進行三倍。儘管進行了大量研究，但開發有效治療的進展仍然緩慢，而且大多數可用的療法僅提供臨時緩解症狀，而不是解決神經報導的潛在原因。

Alzheimer's Cure Charity Token aims to bridge this gap by introducing a community-driven funding model that enables investors, researchers, and medical professionals to collaborate in real-time. By leveraging decentralized funding mechanisms, Alzheimer's Cure Charity Token expedites financial support for promising scientific projects, allowing them to progress more efficiently toward clinical trials and potential FDA approvals.

阿爾茨海默氏症的CURE慈善機構令牌旨在通過引入社區驅動的資金模型來彌合這一差距，該模型使投資者，研究人員和醫療專業人員能夠實時合作。通過利用分散的資金機制，阿爾茨海默氏症的Cure Cure Charity代幣加快了對有希望的科學項目的財政支持，從而使他們能夠更有效地朝著臨床試驗和潛在的FDA批准方面進步。

$ALZcure Partners with YouthBio Therapeutics to Advance Alzheimer's Research

$ alzcure與Youthbio Therapeutics合作，以推進阿爾茨海默氏症的研究

Alzheimer's Cure Charity Token has partnered with YouthBio Therapeutics, a biotech firm specializing in epigenetic rejuvenation and longevity therapies, to accelerate Alzheimer's research.

阿爾茨海默氏症的CURE CHARITY TOKEN已與Foundbio Therapeutics合作，這是一家專門從事表觀遺傳復興和長壽療法的生物技術公司，以加速阿爾茨海默氏症的研究。

YouthBio has been conducting preclinical studies on age-related cognitive decline and Progeria using ARTE10 mice, showing promise in both areas. The company has also received a Rare Pediatric Disease Designation from the FDA for Progeria, making it eligible for a Priority Review Voucher (PRV)-a designation that could fast-track future treatments.

Youthbio一直在使用ARTE10小鼠對與年齡相關的認知下降和後代進行臨床前研究，這在這兩個地區都有希望。該公司還從FDA獲得了FDA的罕見兒科疾病名稱，使其有資格獲得優先審查憑證（PRV） - 可以快速訓練未來治療的指定。

With plans to initiate human trials in Australia, YouthBio is currently working with local regulators and engaging with the FDA for an Investigational New Drug (IND) filing in the U.S. This collaboration aligns with Alzheimer's Cure Charity Token's mission to support cutting-edge biotech research through decentralized funding, helping to speed up the development of groundbreaking therapies for Alzheimer's and other neurodegenerative diseases.

With plans to initiate human trials in Australia, YouthBio is currently working with local regulators and engaging with the FDA for an Investigational New Drug (IND) filing in the US This collaboration aligns with Alzheimer's Cure Charity Token's mission to support cutting-edge biotech research through decentralized funding, helping to speed up the development of groundbreaking therapies for Alzheimer's and other neurodegenerative diseases.